A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (CheckMate 459: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459)
A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (CheckMate 459: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459)
The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma.
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Kurume-shi, Fukuoka 8300011, Japan
Ogaki-shi, Gifu 5038502, Japan
Kawasaki-shi, Kanagawa 2138587, Japan
Osaka-Sayama-Shi, Osaka 5898511, Japan
Chiyoda-ku, Tokyo 101-0062, Japan
Mitaka-shi, Tokyo 181-8611, Japan
Musashino-shi, Tokyo 180-8610, Japan
Shinjuku-ku, Tokyo 1628655, Japan
Jeollanam-do, 58128, South Korea
Majadahonda - Madrid, 28222, Spain
Santiago Compostela, 15706, Spain
Kaohsiung County, 83301, Taiwan
Taoyuan County, 33305, Taiwan